Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Extension to Study ZS-004 [Phase 3 Multicenter, Multi-phase, Multi-dose, Prospective, Randomized, Double-blind, Placebo-controlled Maintenance Study of Safety Efficacy of ZS (Sodium Zirconium Cycolsilicate) in Hyperkalemia.]

NCT02107092 is registered in ClinicalTrials.gov with ZS Pharma, Inc. as lead sponsor.

NCT NCT02107092
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02107092 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Extension to Study ZS-004 [Phase 3 Multicenter, Multi-phase, Multi-dose, Prospective, Randomized, Double-blind, Placebo-controlled Maintenance Study of Safety Efficacy of ZS (Sodium Zirconium Cycolsilicate) in Hyperkalemia.]
Lead sponsor
ZS Pharma, Inc.
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2014
Completion date
August 31, 2015
Enrollment
123 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

hyperkalemia